Published in Health Business Week, February 9th, 2007
The IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) trial is a multicenter phase 2 clinical study aimed at preventing a severe respiratory complication of sickle cell disease, acute chest syndrome. Acute chest syndrome, a form of acute lung injury, is the leading cause of death in sickle cell disease patients. It commonly follows admission to the hospital for other reasons, especially an episode of bone pain (a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.